A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
To conduct a randomized dose-ranging study to evaluate the safety and activity of orally
administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic
HIV-1 infection. The primary endpoints of the study will include an increase or upregulation
in genes known to be mediators of interferon response. Secondary endpoints will include the
absolute CD4 count and plasma HIV RNA levels.